346 related articles for article (PubMed ID: 34408400)
21. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer.
Wang W; Lei W; Fang Z; Jiang R; Wang X
BMC Cancer; 2024 Jan; 24(1):1. PubMed ID: 38166784
[TBL] [Abstract][Full Text] [Related]
23. Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study.
Wu J; Xie Z; Xiao Y; Wang B; Zhang P
Medicine (Baltimore); 2022 Oct; 101(40):e30922. PubMed ID: 36221419
[TBL] [Abstract][Full Text] [Related]
24. Nomogram-Predicted Survival of Breast Cancer Brain Metastasis: a SEER-Based Population Study.
Xiong Y; Cao H; Zhang Y; Pan Z; Dong S; Wang G; Wang F; Li X
World Neurosurg; 2019 Aug; 128():e823-e834. PubMed ID: 31096027
[TBL] [Abstract][Full Text] [Related]
25. Establishment and Validation of a Nomogram for Nasopharyngeal Carcinoma Patients Concerning the Prognostic Effect of Parotid Lymph Node Metastases.
Lin C; Sun XS; Liu SL; Li XY; Lu N; Li XL; Tang LQ; Guo L
Cancer Res Treat; 2020 Jul; 52(3):855-866. PubMed ID: 32164051
[TBL] [Abstract][Full Text] [Related]
26. A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer.
Lin M; Jin Y; Jin J; Wang B; Hu X; Zhang J
Cancer Med; 2020 Nov; 9(22):8540-8551. PubMed ID: 32945619
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study.
Lyu X; Luo B
Cancer Med; 2021 Nov; 10(22):8114-8126. PubMed ID: 34612593
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
He CB; Lao XM; Lin XJ
Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
[TBL] [Abstract][Full Text] [Related]
29. Construction and validation of a nomogram to predict overall survival in patients with inflammatory breast cancer.
Diao JD; Ma LX; Sun MY; Wu CJ; Wang LJ; Liu YL; Yang YJ
Cancer Med; 2019 Sep; 8(12):5600-5608. PubMed ID: 31407527
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of nomograms predicting survival in Chinese patients with triple negative breast cancer.
Yang Y; Wang Y; Deng H; Tan C; Li Q; He Z; Wei W; Zhou E; Liu Q; Liu J
BMC Cancer; 2019 Jun; 19(1):541. PubMed ID: 31170946
[TBL] [Abstract][Full Text] [Related]
31. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer.
Wang W; Sun Z; Deng JY; Qi XL; Feng XY; Fang C; Ma XH; Wang ZN; Liang H; Xu HM; Zhou ZW
Cancer Commun (Lond); 2018 May; 38(1):23. PubMed ID: 29764518
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of prognostic nomograms for patients with metastatic prostate cancer.
Jiang WD; Yuan PC
Int Urol Nephrol; 2019 Oct; 51(10):1743-1753. PubMed ID: 31289983
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
Blanchette PS; Desautels DN; Pond GR; Bartlett JMS; Nofech-Mozes S; Yaffe MJ; Pritchard KI
Breast Cancer Res Treat; 2018 Jul; 170(1):169-177. PubMed ID: 29520532
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Value of Modified IHC4 Score in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Jin L; Chen K; Tan C; Li J; Luo J; Yang Y; Li Y; Li S; Zhu L; Hu Y; Liu F; You Q; Peng M; Jiang Z; Liu Q
Oncologist; 2020 Aug; 25(8):e1170-e1180. PubMed ID: 32476192
[TBL] [Abstract][Full Text] [Related]
35. Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors.
Chen X; Li Z; Zhou J; Wei Q; Wang X; Jiang R
PeerJ; 2022; 10():e14566. PubMed ID: 36540802
[TBL] [Abstract][Full Text] [Related]
36. Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.
Koleva-Kolarova RG; Oktora MP; Robijn AL; Greuter MJW; Reyners AKL; Buskens E; de Bock GH
Cancer Treat Rev; 2017 Apr; 55():16-25. PubMed ID: 28288388
[TBL] [Abstract][Full Text] [Related]
37. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
Bringolf L; Pestalozzi B; Fink D; Dedes K
Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
[TBL] [Abstract][Full Text] [Related]
38. Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US.
Li N; Hao Y; Kageleiry A; Peeples M; Fang A; Koo V; Wu EQ; Guérin A
Curr Med Res Opin; 2016; 32(2):385-94. PubMed ID: 26651842
[TBL] [Abstract][Full Text] [Related]
39. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
40. Establishing a predicted model to evaluate prognosis for initially diagnosed metastatic Her2-positive breast cancer patients and exploring the benefit from local surgery.
Lin H; Wu Y; Liang G; Chen L
PLoS One; 2020; 15(11):e0242155. PubMed ID: 33170907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
